The US Food and Drug Administration (FDA) has extended the review period for United States-based Incyte's supplemental new drug application (NDA) for acute graft-versus-host disease (GVHD) treatment, Jakafi (ruxolitinib), it was reported on Friday.
24 May is the new Prescription Drug User Fee Act (PDUFA) target action date for Jakafi, which is for the treatment of patients with GVHD who have had an inadequate response to corticosteroids. The FDA has extended the action date to allow time to evaluate additional data provided by the company in response to the regulator's information requests. It has determined that submitted additional information is required to constitute a major amendment to the supplemental NDA, enabling it to extend the PUDFA goal date by three months.
In August 2018, Incyte submitted a supplemental NDA for ruxolitinib intended to treat patients with acute GVHD. Ruxolitinib secured priority review and breakthrough therapy designation from the US FDA.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT